Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation
Xu Tan(Shantou University), Shifeng Lou(Dalian Medical University), Li Gao(Army Medical University), Xiaoqi Wang(Army Medical University), Xi Zhang(Army Medical University), Cheng Zhang(Army Medical University), Wen Qin(Army Medical University), Chen Guo(Army Medical University), Yan Shen(Fudan University), Yingying Ma(Army Medical University), Han Yao(Army Medical University), Lei Gao(Second Military Medical University), Peiyan Kong(Army Medical University)
Cited by 8
Related Papers
Recent advances in CAR-T cell engineering
|Journal of Hematology & Oncology|2020|403
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
|Cancer Cell|2020|234
TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair
|Frontiers in Oncology|2019|115
Strategies to enhance CAR-T persistence
|Biomarker Research|2022|90
Characteristics of acute myeloid leukemia with myelodysplasia‐related changes: A retrospective analysis in a cohort of <scp>Chinese</scp> patients
|American Journal of Hematology|2014|56